The BCL2-family of protein ligands as cancer drugs

The next generation of therapeutics

Wen Jing Liu, Anca Bulgaru, Missak Haigentz, C. A. Stein, Roman Perez-Soler, Sridhar Mani

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Selective aberrant cell suicide (ie., apoptosis or programmed cell death) is a hallmark of "nonneoplastic" tissue. In cells that have clonally evolved or in common parlance "cancer cells", apoptosis is either itself aberrant or completely inhibited. Strategies to enhance apoptosis under conditions of cancer cellular stress is an evolving and actively investigated area of experimental therapeutics. Bcl2 proteins are key mediators of the process of apoptosis and ligands to these family of proteins have been described using modern combinatorial, computational and evolutionary small molecule screening approaches. Crystallization of several of the Bcl2 family members has provided clarification of the role of these ligands and provided a clearer mechanism of action for the consequences of ligand binding. In several cases, these ligands (e.g., HA14-1, 2-methoxy antimycin A) induce apoptosis even under conditions of Bcl2 overexpression and if developed preclinically will be promising anticancer agents. This rationale becomes even more striking when one observes overexpression of Bcl2 in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer.

Original languageEnglish (US)
Pages (from-to)217-223
Number of pages7
JournalCurrent Medicinal Chemistry - Anti-Cancer Agents
Volume3
Issue number3
DOIs
StatePublished - May 7 2003
Externally publishedYes

Fingerprint

Proto-Oncogene Proteins c-bcl-2
Apoptosis
Ligands
Pharmaceutical Preparations
Neoplasms
Antimycin A
Therapeutics
B-Cell Lymphoma
Crystallization
Antineoplastic Agents
Suicide
Prostatic Neoplasms
Proteins
Adenocarcinoma
Cell Death
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Cancer Research

Cite this

Liu, Wen Jing ; Bulgaru, Anca ; Haigentz, Missak ; Stein, C. A. ; Perez-Soler, Roman ; Mani, Sridhar. / The BCL2-family of protein ligands as cancer drugs : The next generation of therapeutics. In: Current Medicinal Chemistry - Anti-Cancer Agents. 2003 ; Vol. 3, No. 3. pp. 217-223.
@article{9104ed7838fc48c78f9e3f87e3d5f8cb,
title = "The BCL2-family of protein ligands as cancer drugs: The next generation of therapeutics",
abstract = "Selective aberrant cell suicide (ie., apoptosis or programmed cell death) is a hallmark of {"}nonneoplastic{"} tissue. In cells that have clonally evolved or in common parlance {"}cancer cells{"}, apoptosis is either itself aberrant or completely inhibited. Strategies to enhance apoptosis under conditions of cancer cellular stress is an evolving and actively investigated area of experimental therapeutics. Bcl2 proteins are key mediators of the process of apoptosis and ligands to these family of proteins have been described using modern combinatorial, computational and evolutionary small molecule screening approaches. Crystallization of several of the Bcl2 family members has provided clarification of the role of these ligands and provided a clearer mechanism of action for the consequences of ligand binding. In several cases, these ligands (e.g., HA14-1, 2-methoxy antimycin A) induce apoptosis even under conditions of Bcl2 overexpression and if developed preclinically will be promising anticancer agents. This rationale becomes even more striking when one observes overexpression of Bcl2 in 70{\%} of breast cancer, 30-60{\%} of prostate cancer, 80{\%} of B-cell lymphomas, 90{\%} of colorectal adenocarcinomas, and many other forms of cancer.",
author = "Liu, {Wen Jing} and Anca Bulgaru and Missak Haigentz and Stein, {C. A.} and Roman Perez-Soler and Sridhar Mani",
year = "2003",
month = "5",
day = "7",
doi = "10.2174/1568011033482459",
language = "English (US)",
volume = "3",
pages = "217--223",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

The BCL2-family of protein ligands as cancer drugs : The next generation of therapeutics. / Liu, Wen Jing; Bulgaru, Anca; Haigentz, Missak; Stein, C. A.; Perez-Soler, Roman; Mani, Sridhar.

In: Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, No. 3, 07.05.2003, p. 217-223.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The BCL2-family of protein ligands as cancer drugs

T2 - The next generation of therapeutics

AU - Liu, Wen Jing

AU - Bulgaru, Anca

AU - Haigentz, Missak

AU - Stein, C. A.

AU - Perez-Soler, Roman

AU - Mani, Sridhar

PY - 2003/5/7

Y1 - 2003/5/7

N2 - Selective aberrant cell suicide (ie., apoptosis or programmed cell death) is a hallmark of "nonneoplastic" tissue. In cells that have clonally evolved or in common parlance "cancer cells", apoptosis is either itself aberrant or completely inhibited. Strategies to enhance apoptosis under conditions of cancer cellular stress is an evolving and actively investigated area of experimental therapeutics. Bcl2 proteins are key mediators of the process of apoptosis and ligands to these family of proteins have been described using modern combinatorial, computational and evolutionary small molecule screening approaches. Crystallization of several of the Bcl2 family members has provided clarification of the role of these ligands and provided a clearer mechanism of action for the consequences of ligand binding. In several cases, these ligands (e.g., HA14-1, 2-methoxy antimycin A) induce apoptosis even under conditions of Bcl2 overexpression and if developed preclinically will be promising anticancer agents. This rationale becomes even more striking when one observes overexpression of Bcl2 in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer.

AB - Selective aberrant cell suicide (ie., apoptosis or programmed cell death) is a hallmark of "nonneoplastic" tissue. In cells that have clonally evolved or in common parlance "cancer cells", apoptosis is either itself aberrant or completely inhibited. Strategies to enhance apoptosis under conditions of cancer cellular stress is an evolving and actively investigated area of experimental therapeutics. Bcl2 proteins are key mediators of the process of apoptosis and ligands to these family of proteins have been described using modern combinatorial, computational and evolutionary small molecule screening approaches. Crystallization of several of the Bcl2 family members has provided clarification of the role of these ligands and provided a clearer mechanism of action for the consequences of ligand binding. In several cases, these ligands (e.g., HA14-1, 2-methoxy antimycin A) induce apoptosis even under conditions of Bcl2 overexpression and if developed preclinically will be promising anticancer agents. This rationale becomes even more striking when one observes overexpression of Bcl2 in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0242500957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242500957&partnerID=8YFLogxK

U2 - 10.2174/1568011033482459

DO - 10.2174/1568011033482459

M3 - Review article

VL - 3

SP - 217

EP - 223

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 3

ER -